Summary:
Tralokinumab monotherapy for moderate to severe atopic dermatitis.
Qualified Participants Must:
• Be 18 years of age or older
•
Have a atopic dermatitis disgnosis for at least 1 year
•
Have had inadequate response to topical treatment withing one year
•
Have at least 10 percent or more body surface covered with atopic dermatitis
Qualified Participants May Receive:
Study visits and medication at no cost as well as compensation for time and travel.